Dianthus (DNTH) Therapeutics announced that it has commenced an underwritten public offering of $150M of its shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities are being offered by Dianthus. Dianthus intends to use the net proceeds from this offering to advance the Company’s preclinical and clinical development activities, as well as for working capital and general corporate purposes. Jefferies, TD Cowen, Evercore ISI and Stifel are acting as joint book-running managers for the proposed offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus price target raised to $100 from $92 at Guggenheim
- EchoStar sells spectrum licenses to SpaceX, StubHub to launch IPO: Morning Buzz
- Promising Phase II Results and Market Potential Drive Buy Rating for Dianthus Therapeutics
- Promising Clinical Data and Strategic Plans Support Buy Rating for Dianthus Therapeutics
- Dianthus gMG data has positive read through to other indications, says Jefferies